Control of cyclic oligoadenylate synthesis in a type III CRISPR system.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29963983.
- Also identified by DOI 10.7554/eLife.36734 and PMC identifier 6053304.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The CRISPR system for prokaryotic adaptive immunity provides RNA-mediated protection from viruses and mobile genetic elements. When viral RNA transcripts are detected, type III systems adopt an activated state that licenses DNA interference and synthesis of cyclic oligoadenylate (cOA). cOA activates nucleases and transcription factors that orchestrate the antiviral response. We demonstrate that cOA synthesis is subject to tight temporal control, commencing on target RNA binding, and is deactivated rapidly as target RNA is cleaved and dissociates. Mismatches in the target RNA are well tolerated and still activate the cyclase domain, except when located close to the 3' end of the target. Phosphorothioate modification reduces target RNA cleavage and stimulates cOA production. The 'RNA shredding' activity originally ascribed to type III systems may thus be a reflection of an exquisite mechanism for control of the Cas10 subunit, rather than a direct antiviral defence.
Medical subject headings
- Adenine Nucleotides
- CRISPR-Cas Systems
- Endodeoxyribonucleases
- Oligoribonucleotides
- RNA Viruses
- RNA, Viral
- Sulfolobus solfataricus